Table 2 Effects of Product Characteristics on Symptom Relief.

From: The Association between Cannabis Product Characteristics and Symptom Relief

Outcome = Symptom Change (Ending - Starting Symptom)
  (1) (2) (3) (4) (5)
Panel A: Product Type, omitted category = flower
Concentrate 0.194**     0.080
(0.076)     (0.212)
Edible 0.340***     
(0.105)     
Tincture 0.498***     
(0.117)     
Topical −0.216     
(0.355)     
Panel B: Subspecies, omitted category = hybrid
C. indica   −0.103**    −0.057
  (0.041)    (0.083)
C. sativa   0.096*    0.195
  (0.055)    (0.121)
Panel C: Combustion Method, omitted category = joint
Pipe    −0.061   −0.004
   (0.084)   (0.194)
Vape    0.051   0.051
   (0.092)   (0.210)
Panel D: THC and CBD, omitted categories = THC < 10% and CBD < 1%
THC 10–19%     −0.215* −0.220*
    (0.117) (0.134)
THC 20–34%     −0.235** −0.315***
    (0.112) (0.121)
THC 35%+     −0.252** −0.342**
    (0.126) (0.166)
CBD 1–9%     −0.089 −0.026
    (0.121) (0.126)
CBD 10–34%     0.038 0.079
    (0.105) (0.092)
CBD 35%+     −0.222 −0.241
    (0.209) (0.227)
Starting Symptom Level −0.704*** −0.721*** −0.726*** −0.709*** −0.717***
(0.028) (0.031) (0.032) (0.056) (0.063)
Constant 0.588*** 0.691*** 0.719*** 0.909*** 0.850**
(0.165) (0.184) (0.212) (0.340) (0.403)
Number of sessions 19,910 17,197 16,898 4,439 3,869
R-squared 0.330 0.340 0.338 0.337 0.346
Number of users 3,341 2,996 2,936 900 787
  1. Notes: Regressions control for individual user fixed effects. Concentrate is relative to Flower, C. indica and C. sativa are relative to Hybrid, THC categories are relative to THC 0–9%, CBD categories are relative to CBD 0%, and Pipe and Vape are relative to Joint. Standard errors are clustered at the user level (shown in parentheses). ***p < 0.01, **p < 0.05, *p < 0.1.